Federated Hermes, Inc. Neurocrine Biosciences Inc Transaction History

Federated Hermes, Inc.

$43.6 Billion
Q3 2024

A detailed history of Federated Hermes, Inc. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Federated Hermes, Inc. holds 88,922 shares of NBIX stock, worth $11.2 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

88,922

Previous 111,055 19.93%

Holding current value

$11.2 Million

Previous $15.3 Million 33.04%

% of portfolio

0.02%

Previous 0.04%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$114.58 - $153.15 $2.54 Million - $3.39 Million	-22,133 Reduced 19.93%	88,922 $10.2 Million
Q2 2024 Aug 08, 2024	BUY	$130.86 - $143.19 $499,623 - $546,699	3,818 Added 3.56%	111,055 $15.3 Million
Q1 2024 May 14, 2024	SELL	$130.4 - $143.74 $174,736 - $192,611	-1,340 Reduced 1.23%	107,237 $14.8 Million
Q4 2023 Jan 31, 2024	SELL	$106.07 - $132.76 $178,727 - $223,700	-1,685 Reduced 1.53%	108,577 $14.3 Million
Q3 2023 Nov 13, 2023	BUY	$94.02 - $117.1 $1.2 Million - $1.5 Million	12,815 Added 13.15%	110,262 $12.4 Million
Q2 2023 Aug 14, 2023	BUY	$89.53 - $104.87 $1.52 Million - $1.78 Million	16,986 Added 21.11%	97,447 $9.19 Million
Q1 2023 May 08, 2023	BUY	$94.11 - $123.02 $4.07 Million - $5.32 Million	43,249 Added 116.22%	80,461 $8.14 Million
Q4 2022 Feb 13, 2023	BUY	$106.72 - $127.06 $2.35 Million - $2.8 Million	22,066 Added 145.69%	37,212 $4.44 Million
Q3 2022 Nov 14, 2022	SELL	$92.03 - $107.81 $155,990 - $182,737	-1,695 Reduced 10.06%	15,146 $1.61 Million
Q2 2022 Aug 15, 2022	SELL	$75.79 - $100.07 $1.23 Million - $1.63 Million	-16,269 Reduced 49.14%	16,841 $1.64 Million
Q1 2022 May 13, 2022	SELL	$72.45 - $94.81 $331,096 - $433,281	-4,570 Reduced 12.13%	33,110 $3.1 Million
Q4 2021 Feb 14, 2022	SELL	$79.65 - $106.22 $157,308 - $209,784	-1,975 Reduced 4.98%	37,680 $3.21 Million
Q3 2021 Nov 15, 2021	SELL	$86.18 - $99.03 $2.06 Million - $2.37 Million	-23,890 Reduced 37.6%	39,655 $3.8 Million
Q2 2021 Aug 16, 2021	SELL	$89.43 - $102.27 $7.71 Million - $8.82 Million	-86,225 Reduced 57.57%	63,545 $6.18 Million
Q1 2021 May 13, 2021	BUY	$87.57 - $119.4 $13.1 Million - $17.9 Million	149,720 Added 299440.0%	149,770 $14.6 Million
Q4 2020 Feb 12, 2021	SELL	$86.91 - $108.33 $7.78 Million - $9.7 Million	-89,533 Reduced 99.94%	50 $5,000
Q3 2020 Nov 12, 2020	BUY	$96.16 - $135.15 $3.91 Million - $5.49 Million	40,651 Added 83.08%	89,583 $8.61 Million
Q2 2020 Aug 13, 2020	BUY	$85.09 - $130.36 $1.91 Million - $2.92 Million	22,432 Added 84.65%	48,932 $5.97 Million
Q1 2020 May 13, 2020	SELL	$75.11 - $113.76 $455,016 - $689,158	-6,058 Reduced 18.61%	26,500 $2.29 Million
Q4 2019 Feb 14, 2020	BUY	$86.8 - $118.57 $2.09 Million - $2.85 Million	24,047 Added 282.54%	32,558 $3.5 Million
Q3 2019 Nov 14, 2019	SELL	$83.82 - $101.5 $53,812 - $65,163	-642 Reduced 7.01%	8,511 $767,000
Q2 2019 Aug 14, 2019	SELL	$72.24 - $91.27 $48,906 - $61,789	-677 Reduced 6.89%	9,153 $773,000
Q1 2019 May 10, 2019	SELL	$69.31 - $91.53 $8.02 Million - $10.6 Million	-115,670 Reduced 92.17%	9,830 $866,000
Q4 2018 Feb 13, 2019	SELL	$68.32 - $124.36 $1.84 Million - $3.36 Million	-26,988 Reduced 17.7%	125,500 $8.96 Million
Q3 2018 Nov 13, 2018	BUY	$98.88 - $125.85 $7.14 Million - $9.09 Million	72,224 Added 89.98%	152,488 $18.7 Million
Q2 2018 Aug 10, 2018	SELL	$75.3 - $105.99 $4.95 Million - $6.97 Million	-65,789 Reduced 45.04%	80,264 $7.89 Million
Q1 2018 May 09, 2018	BUY	$75.88 - $92.43 $1.24 Million - $1.52 Million	16,392 Added 12.64%	146,053 $12.1 Million
Q4 2017 Feb 14, 2018	BUY	$58.53 - $77.59 $293,059 - $388,493	5,007 Added 4.02%	129,661 $0
Q3 2017 Nov 13, 2017	BUY	$47.97 - $61.28 $5.98 Million - $7.64 Million	124,654	124,654 $7.64 Million

Others Institutions Holding NBIX

# of Institutions

629

Shares Held

94.2M

Call Options Held

692K

Put Options Held

406K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.

Account

Federated Hermes, Inc. Neurocrine Biosciences Inc Transaction History